Use of in vitro skin penetration data and a physiologically based model to predict in vivo blood levels of benzoic acid.

A physiologically based pharmacokinetic (PB PK) model was developed to predict plasma levels of benzoic acid (BA) in the hairless guinea pig after topical exposure at three finite dose levels. The PB PK model consisted of four compartments: (1) rapidly perfused tissues; (2) slowly perfused tissues; (3) liver, representing the route of elimination of BA from the plasma after biotransformation to hippuric acid; and (4) plasma. The predictive capacity of the PB PK model was assessed by comparing plasma BA levels measured experimentally with those predicted by the model. The percutaneous absorption of finite doses of BA in the model was described by a transdermal input function, which was derived from in vitro percutaneous absorption studies in which viable hairless guinea pig skin in flow-through diffusion cells was exposed to BA. Physiological parameters used in the model were calculated from previously published values. Biochemical parameters, including partition coefficients and metabolic constants, were measured experimentally in vitro. The PB PK model predictions were generally in good agreement with measured plasma levels for each of the dose levels studied. The predicted plasma BA levels and the measured values were closer for the highest dose (120 microg/cm2) than for either of the other two doses used (12 and 40 microg/cm2). The effects of optimizing the metabolic constants and the transdermal input function parameters on the predicted curve shape and fit to that of the measured plasma BA levels were assessed. Varying the transdermal input parameters produced closer agreement between predicted and measured values.